NASDAQ:ABUS Arbutus Biopharma Q4 2025 Earnings Report $4.37 +0.17 (+4.05%) Closing price 04:00 PM EasternExtended Trading$4.37 0.00 (0.00%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Arbutus Biopharma EPS ResultsActual EPS$0.87Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AArbutus Biopharma Revenue ResultsActual Revenue$179.13 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArbutus Biopharma Announcement DetailsQuarterQ4 2025Date3/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsArbutus Biopharma's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Arbutus Biopharma Earnings HeadlinesWall Street Zen Upgrades Arbutus Biopharma (NASDAQ:ABUS) to "Buy"May 16, 2026 | americanbankingnews.comArbutus Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $500 into a fortune while the average stock lost 90% of its value. His son Martin later digitized those same formulas into Weiss Ratings, a system now tracking 22,000 stocks with 1.2 billion daily calculations. That system called the bank failures of the 1980s, the dot-com bust, 2008, and the 2020 crash. Right now it is flashing Code Red - issuing Must-Sell warnings on 10 widely held US stocks and upgrading 3 under-the-radar names to an urgent Buy. Access the full briefing at 79% off during the Memorial Day Savings Event.May 20 at 1:00 AM | Weiss Ratings (Ad)Arbutus Biopharma: A Fascinating HBV Story, But Still Too EarlyMay 13, 2026 | seekingalpha.comArbutus Biopharma (ABUS) Projected to Post Earnings on WednesdayMay 11, 2026 | americanbankingnews.comArbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026May 1, 2026 | finance.yahoo.comSee More Arbutus Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arbutus Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your email. Email Address About Arbutus BiopharmaArbutus Biopharma (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core. In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics. This LNP platform underpins the company’s RNAi assets and has been the foundation for collaborations with other biopharmaceutical organizations seeking efficient delivery systems for mRNA and RNA-based medicines. Arbutus’ focus on innovative delivery solutions complements its antiviral drug discovery capabilities, positioning it at the forefront of HBV research and development. Founded through the merger of Tekmira Pharmaceuticals and OnCore Biopharma, Arbutus maintains dual operations in Warminster, Pennsylvania, and Vancouver, British Columbia. The company’s leadership team combines experience in virology, lipid chemistry and pharmaceutical development, supporting strategic alliances with academic institutions and contract research organizations worldwide. Arbutus continues to engage with global regulatory authorities to advance its clinical trials and seeks partnerships to broaden the reach of its potential HBV therapies.View Arbutus Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Analog Devices Provides Much-Needed Pullback: How Low Can It Go?USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal LoomsFrom Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 OutlookMirum Pharma: A Rare Disease Growth Story to WatchArhaus Stock Drops to 52-Week Low After Q1 EarningsWhy Home Depot’s Sell-Off Could Become a Huge OpportunityPalo Alto Networks Up 70%: Can the Rally Last Into June? Upcoming Earnings NetEase (5/21/2026)Ross Stores (5/21/2026)Walmart (5/21/2026)Deere & Company (5/21/2026)Mitsubishi UFJ Financial Group (5/21/2026)AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
